Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | TTR | P02766 | 1/20 | 0.34 |
| ▸ | ALB | P02768 | 1/20 | 0.34 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28684511 | 0.83 | GPR35 (0.41) | KDM4EHPGDGAAALDH1A1GPR35 | |
| SCHEMBL26091113 | 0.83 | ALDH1A1 (0.42) | KDM4EHPGDGAAALDH1A1CYP11B1 | |
| SCHEMBL30373084 | 0.83 | ALDH1A1 (0.42) | KDM4EHPGDGAAALDH1A1CYP11B1 | |
| SCHEMBL20944039 | 0.81 | GPR35 (0.47) | KDM4EHPGDGAAALDH1A1CYP11B1 | |
| SCHEMBL16411014 | 0.81 | KDM4E (0.44) | KDM4EHPGDGAAALDH1A1CYP11B1 | |
| SCHEMBL26094739 | 0.81 | KDM4E (0.42) | KDM4EHPGDGAAALDH1A1GPR35 | |
| SCHEMBL26091528 | 0.81 | KDM4E (0.36) | KDM4EHPGDGAAALDH1A1SOS1 | |
| SCHEMBL31485922 | 0.80 | MAP2K1 (0.40) | KDM4EGPR35MAP2K1MEN1KMT2A | |
| SCHEMBL409948 | 0.79 | MEN1 (0.50) | GAAALDH1A1CYP11B1CYP11B2LMNA | |
| SCHEMBL6119252 | 0.78 | SOS1 (0.42) | KDM4EGAASOS1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116868-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2026-04-30 | — | — | US | disclosed |
| WO-2025076299-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2025-04-10 | — | — | WO | disclosed |
| CN-108698992-B | 2-cyanoisoindoline derivatives for the treatment of cancer | 特殊治疗有限公司 | 2022-04-19 | — | — | CN | disclosed |
| EP-3429994-B1 | 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER | MISSION THERAPEUTICS LTD (GB) | 2021-06-16 | — | — | EP | disclosed |
| US-10683269-B2 | 2-cyanoisoindoline derivatives for treating cancer | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-16 | — | — | US | disclosed |
| EP-3429994-A1 | 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER | Mission Therapeutics Limited (GB) | 2019-01-23 | — | — | EP | disclosed |
| US-20190010122-A1 | 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER | MISSION THERAPEUTICS LIMITED (GB) | 2019-01-10 | — | — | US | disclosed |
| WO-2017158388-A1 | 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER | MISSION THERAPEUTICS LIMITED (GB) | 2017-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190010122-A1 | 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER | USP7, USP47, USP2 | KDM4E 352/4885HPGD 1770/4885GAA 641/4885 |
| US-20260116868-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | CBLB, CBLC, CBL | KDM4E 2320/4885HPGD 4659/4885GAA 1767/4885 |
| US-10683269-B2 | 2-cyanoisoindoline derivatives for treating cancer | USP7, USP47, USP2 | KDM4E 352/4885HPGD 1770/4885GAA 641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.